A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer

Ngā tūemi rite

• A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
  mā: Benjamin W. Fischer-Valuck, me ētahi atu.
  I whakaputaina: (2019-12-01)
• A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
  mā: Damián Guirado, me ētahi atu.
  I whakaputaina: (2020-04-01)
• High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
  mā: Bengt Johansson, me ētahi atu.
  I whakaputaina: (2021-05-01)
• The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
  mā: Wojciech M. Burchardt, me ētahi atu.
  I whakaputaina: (2023-04-01)
• High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up
  mā: Manuel Behmueller, me ētahi atu.
  I whakaputaina: (2021-12-01)